All In Biotech

Investigational drug · Phase 2

Valaciclovir

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

144

Any phase or sponsor naming "Valaciclovir"

First trial start

2026

Apr 21, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Valaciclovir", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Glioblastoma (GBM)
  • High Grade Gliomas
  • Recurrent Glioblastoma
  • Newly Diagnosed Glioblastoma

Approved drugs for the same conditions: Brain tumors (glioma) · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Valaciclovir" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 546 on PubMed

Also in development for Glioblastoma (GBM)

  • BreakVaxPhase 22 trials

    BreakBio Corp · Triple-Negative Breast Cancer (TNBC), Glioblastoma (GBM)

  • DOC1021Phase 22 trials

    Diakonos Oncology Corporation · Glioblastoma (GBM), Refractory Melanoma

  • MT-125Phase 22 trials

    Myosin Therapeutics Inc. · Glioblastoma (GBM), Glioblastoma

  • silevertinibBDTX-1535Phase 22 trials

    Black Diamond Therapeutics, Inc. · Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM

  • JBI-778Phase 21 trial

    Jubilant Therapeutics Inc. · Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG)

  • TGX-007Phase 21 trial

    Trogenix ltd · Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.